Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
ELMIRON (pentosan polysulfate sodium) is an oral small-molecule NDA approved in 1996 for interstitial cystitis and knee osteoarthritis. The mechanism of action and pharmacologic class are not specified in available data. The product is approaching loss of exclusivity, indicating mature lifecycle status with potential generic competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
Worked on ELMIRON at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero open positions are currently linked to ELMIRON, suggesting minimal active recruitment for this product team. Typical roles on declining-exclusivity products focus on generic transition management, compliance, and market defense rather than growth initiatives. Relevant skills include managed markets expertise, payer relations, and risk management for safety signals such as ophthalmologic monitoring.